Targeting CDC7 sensitizes resistance melanoma cells to BRAF(V600E)-specific inhibitor by blocking the CDC7/MCM2-7 pathway

Although the utilization of selective BRAF(V600E) inhibitors is associated with improved overall survival in patients with metastatic melanoma, a growing challenge of drug resistance has  emerged. CDC7 has been shown to be overexpressed and associated with poor prognosis in various cancers including...

Descripción completa

Detalles Bibliográficos
Autores principales: Gad, Shaimaa A., Ali, Hamdy E. A., Gaballa, Rofaida, Abdelsalam, Rania M., Zerfaoui, Mourad, Ali, Hamed I., Salama, Salwa H., Kenawy, Sanaa A., Kandil, Emad, Abd Elmageed, Zakaria Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775054/
https://www.ncbi.nlm.nih.gov/pubmed/31578454
http://dx.doi.org/10.1038/s41598-019-50732-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6775054/
https://www.ncbi.nlm.nih.gov/pubmed/31578454
http://dx.doi.org/10.1038/s41598-019-50732-w

Ejemplares similares